Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Short, K Detweiler, Rajkumar, SV, Larson, D, Buadi, F, Hayman, S, Dispenzieri, A, Gertz, M, Kumar, S, Mikhael, J, Roy, V, Kyle, RA, Lacy, MQ
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736849/
https://ncbi.nlm.nih.gov/pubmed/21350560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.29
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki